Results 61 to 70 of about 12,608 (240)
Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo‐controlled studies of varenicline [PDF]
Journal of Diabetes Investigation, 2016 AbstractAims/IntroductionStopping smoking deserves high priority in preventing complications of diabetes; however, only sparse data are available regarding the efficacy of pharmacotherapy in smokers with diabetes. We assessed the efficacy and safety of varenicline in smokers with diabetes who participated in 15 double‐blind, randomized, placebo ...
David Lawrence, Serena Tonstad
openaire +3 more sources
Asia-Pacific Journal of Clinical Oncology, EarlyView.The data on the smoking cessation practices of oncology HCPs found that differences existed between specialties and provision was more likely for those who had received training. A greater understanding of referral to behavioural support and pharmacotherapy is required through training for all staff involved in oncology patient care.
Alison Luk Young +23 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.We report a poisoning with paliperidone palmitate, a once‐monthly, long‐acting injectable antipsychotic. The patient suffered from deep sedation and dystonia. She had been treated with extended release intramuscular paliperidone for several years and had received her last injection 8 days prior to admission.
Mariam Nersesjan +5 more
wiley +1 more source
Visual hallucinations associated with varenicline: a case report
Journal of Medical Case Reports, 2009 Introduction Varenicline is widely used for smoking cessation. It has shown efficacy over placebo and bupropion in manufacturer-sponsored trials. Those with mental illness were excluded from these trials.
Raidoo B Mahendri, Kutscher Eric C
doaj +1 more source
BMC Medicine, 2020 Background Varenicline, bupropion and nicotine replacement therapy (NRT) are three effective pharmacotherapies for smoking cessation, but data about their safety in pregnancy are limited.
Duong Thuy Tran +7 more
doaj +1 more source
Varenicline as a Cause of Suicidal Outcomes [PDF]
Nicotine & Tobacco Research, 2015 Postmarketing analyses and case reports have associated varenicline use with suicidal behaviors. This article reviews postmarketing analyses, case reports, clinical trials, uncontrolled observational studies, controlled observational studies, and studies in smokers with psychiatric problems that have tested this association.The author searched the ...
openaire +3 more sources
Journal of Clinical Psychopharmacology, 2019 Background Neuropsychiatric safety and relative efficacy of varenicline, bupropion, and transdermal nicotine patch (NRT) in those with psychiatric disorders are of interest.
A. E. Evins +9 more
semanticscholar +1 more source
Addictive Behaviors Reports, 2018 Introduction: The degree to which smokers quit successfully with varenicline is strongly associated with their adherence to the medication regimen. Thus, measuring varenicline adherence to identify smokers needing additional intervention is a priority ...
Grace Crawford +8 more
doaj
Comparative Effectiveness of Smoking Cessation Medications: A National Prospective Cohort From Taiwan. [PDF]
PLoS ONE, 2016 Relative effectiveness of smoking cessation medications-varenicline, bupropion and nicotine replacement therapy (NRT)-remains unclear among smokers in real-world settings.
Po-Yin Chang +4 more
doaj +1 more source
Varenicline overdose in a teenager [PDF]
Clinical Toxicology, 2009 Varenicline (Chantix®) is a selective partial agonist of α4β2 nicotinic acetylcholine receptor subtypes. It is approved in the United States to aid with smoking cessation.
Amy Joy Hedlund +3 more
openaire +2 more sources